Researchers in the United Kingdom have begun testing a new artificial intelligence-designed “universal” coronavirus vaccine that scientists believe could help protect against future virus outbreaks and reduce the risk of another global pandemic.
The experimental vaccine was developed by researchers at University of Cambridge alongside biotech company DIOSynVax using large-scale genetic data collected from global virus surveillance programmes.
Scientists focused on a broad group of coronaviruses known as Sarbecoviruses, which includes COVID-19 and the virus responsible for SARS.
Using artificial intelligence modelling, researchers created what they described as a “super antigen” by combining shared features found across multiple coronaviruses. The aim is to train the immune system to recognise and fight a wide range of related viruses, including future strains that may emerge through mutation.
The vaccine has already entered an early-stage clinical trial involving 39 healthy volunteers at University Hospital Southampton and a partner facility at Addenbrooke’s Hospital in Cambridge.
Researchers said the vaccine triggered immune responses against SARS-CoV-2, SARS and several bat coronaviruses that could potentially spread to humans in the future.
According to the scientists, this is the first time a vaccine whose central design was generated entirely through computer simulations has been tested in humans.
Early findings published in the Journal of Infection showed that the vaccine appeared safe and produced no major side effects.
Professor Saul Faust, the chief investigator of the trial, said existing vaccine systems often struggle to keep up with rapidly evolving viruses.
He explained that the new AI-driven approach could move vaccine development from a reactive model to a more proactive form of protection.
Professor Jonathan Heeney described the project as a move toward “future-proof” vaccine design capable of protecting people against multiple viral strains and related emerging threats.
Researchers also revealed that the vaccine uses a DNA platform and is administered through a needle-free microfluid jet delivery system.
Although the initial results are encouraging, scientists stressed that larger Phase 2 clinical trials will still be required before the vaccine can be approved for widespread public use.
Experts involved in the project said the innovation could represent a major breakthrough in pandemic preparedness and global health security.





